Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

A trial drug has kept Desiree Dufour's breast cancer at bay — and now, the medication has been approved by the FDA. She has ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

where sales are dominated by small molecules like Ibrance (palbociclib) for breast cancer, prostate cancer therapy Xtandi (enzalutamide), and Inlyta (axitinib) for kidney cancer. That shift could ...

The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus ...

The U.S. Food and Drug Administration (FDA) recently approved Itovebi in combination with palbociclib and fulvestrant, for the treatment of adults with Under the terms of the agreement ...

The breast cancer drug Ibrance (palbociclib), ranked eighth, has emerged as a big earner for Pfizer, which is testing the drug on several other cancers. "Johnson & Johnson and Mitsubishi Tanabe ...

According to figures from the Reserve Bank of India, there were 215,000 ATMs in India at the end of September 2024, down from 219,000 the previous year.